An American company I’m familiar with has made a great breakthrough in the management of diabetes. Excerpt:
On Wednesday, the FDA approved Medtronic’s hybrid closed-loop system, the world’s first “artificial pancreas.” The agency nod comes months ahead of the spring approval that the company had been expecting.
The MiniMed 670G hybrid closed-loop system is the first FDA-approved device that continuously measures glucose levels and delivers the appropriate dose of basal insulin, according to an FDA statement. It is indicated for people aged 14 or older with Type 1 diabetes and is intended to regulate insulin levels with “little to no input” from the patient, the FDA said in the statement.
“This first-of-its-kind technology can provide people with Type 1 diabetes greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin,” said Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, in the statement.
The system comprises Medtronic’s MiniMed 670G insulin pump that is strapped to the body, an infusion patch that delivers insulin via catheter from the pump and a sensor that measures glucose levels under the skin and can be worn for 7 days at a time. While the device regulates basal, or background, insulin, users must still manually request bolus insulin at mealtimes.
Every profit-making industry produces value in one way or another, or they wouldn’t remain in existence. The medical industry, including devices, pharmaceuticals and biotech, is no exception. But while many industries improve people’s lives in one way or another, medical manufacturers have the potential to actually save lives.
I remind myself of that from time to time, and some Monday mornings that makes getting up and getting to work a little easier.